Offers announced preliminary top collection results from PROPEL.

Based on the American Cancer Culture, approximately 66,000 patients are anticipated to be identified as having NHL in the United States in 2008. The Company estimates the existing annual prevalence of PTCL at 9 approximately,500 patients. There are currently no pharmaceutical agents approved for use in the treating either relapsed or first-line or refractory PTCL. In addition to the 30-50 percent of PTCL patients who do not respond to first-line treatment, a significant number of first-line multi-agent chemotherapy responders relapse or become refractory after treatment.Ms. Hilado spent more than 17 years withGeneral Motors Company, in a variety of responsible positions most notably Assistant Treasurer from 2006 to 2008 increasingly, and previouslyCFO GMAC Industrial Financing LLCfrom 2001 to 2005. She also held positions in the capital markets, business development, world-wide pension and funding analysis and abroad financing functions. She began her career withFar East Trust and Bank Company,Manila, Philippines. Ms. Hilado serves on the Plank of Directors ofH.B. Fuller, and served on the Plank of Directors of Bausch & Lomb previously. She earned a Get better at's in Business Administration from theUniversity of Virginia'sDarden School of Business Administration, and a Bachelor of Science in Management Engineering fromAteneo de Manila Universityinthe Philippines.